Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Dulaglutide

INTERCEPT

Company n/r · Phase n/r · Completed · Enrollment 60000

NCT07417618

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Initiation of dulaglutide, semaglutide or tirzepatiden/rn/rn/rn/r
Initiation of sitagliptinn/rn/rn/rn/r

Not shown

  • Initiation of dulaglutide, semaglutide or tirzepatide: endpoint not reported
  • Initiation of sitagliptin: endpoint not reported